Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis.

Yinzhu Jin Hemin LeeMoa P LeeJoan E LandonJoseph F MerolaRishi J DesaiSeoyoung C Kim

Published in: Arthritis care & research (2021)

Other biologics and apremilast were associated with 1.4- to 3-times higher risk of hospitalized serious infections in PsO/PsA patients when compared with ustekinumab; such safety profile should be considered when selecting appropriate treatment regimens in patients with PsO/PsA.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes
atopic dermatitis